Connect with us
Prague Gaming & TECH Summit 2024

Artificial Intelligence

Human Microbiome market is projected to grow at a CAGR of 25.0% by 2033: Visiongain Reports Ltd

Published

on

<!– Name:DistributionId Value:1000780264 –> <!– Name:EnableQuoteCarouselOnPnr Value:False –> <!– Name:IcbCode Value:2791 –> <!– Name:CustomerId Value:1096632 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:549908c6-ab1f-4779-b498-a26bc0fcc40f –>

Visiongain has published a new report: Human Microbiome Market, (COVID-19 Impact Analysis):- Market Segment by Product (Prebiotics, Medical Drugs, Diagnostic Tests & Skin Products ), Market Segment by Type (Fecal Microbiota Transplant, Live Biotherapeutics Products (LBP), Prebiotics, Post-Biotics & Precision Antibiotics), Market Segment by Technology (Proteomics, Metabolomics, Genomics{16srRNA Sequencing, Shotgun Sequencing and Long Read Metagenomics}), Market Segment by Application (Gastrointestinal, Infectious Diseases, Metabolic Diseases, Cancers, Gut-Brain Axis and Others ), plus COVID-19 Impact Analysis and Recovery Pattern Analysis (“V”-shaped, “W”-shaped, “U”-shaped, “L”-shaped), Profiles of Leading Companies, Region and Countries. 

The human microbiome market was valued at US$186.8 million in 2022 and is projected to grow at a CAGR of 25.0 % during the forecast period 2023-2033. 

Rise in Funding from Private Ventures and Government Institutes to Trigger the Market Growth 

Significant influx of capital has been the main factor driving the growth of human microbiome research. The Government of various countries have displayed their interest in this field and have made significant funding. For instance, NIH (National Institute of Health), U.S. initiated the first Human Microbiome Project in 2007 and supported this project for 10-years until 2016 with a funding amount of US$215 million from 2007 to 2016. While, the European Commission funded Horizon 2020, Human Microbiome project which has been initiated with the aim to boost the microbiome research innovation for tackling the pandemics. The project will be completed by 2024 with a complete duration of 3 years and will be co-ordinated by France’s National Research Institute for Agriculture, Food and Environment. The project has seized a total funding of €44 M (US$46.5 million) in 2019. There are presently three ongoing projects under this initiative which includes Project Oncobiome {€ 14.99 M (US$15.9 million)} (1 January 2019–31 December 2023), Microb-Predict {€ 15.00 M (US$ 15.9 million)} (1 January 2019 – 31 March 2025) and Gemma {€ 14.22 M (US$ 15.0 million} (1 January 2019 – 31 December 2023). Additionally, the European Union aims to fortify its microbiome research through international collaboration at the global level. Despite in its nascent stage, the human microbiome companies have touted attention of the private investors with the U.S. alone garnering a total of US $ 1 billion by 2020 from the year 2015. This funding includes venture funding, corporate and private equity backed companies. The major investors include Seventure Partners, Khosla Ventures, Leaps and JLabs. Players in the market are raising funds by portraying their potential drugs and their unique therapeutic applications. For instance, in March 2022, Microbiotica raised £50m ($67m) to advance its pipeline drugs for immuno-oncology and ulcerative colitis. New investors including Tencent and Flerie, Cambridge Innovation Capital, Seventure Partners and IP Group conducted Series B funding round for Microbiotica. Growing investors both from public and private institutions has boosted the morale of the market. 

Download Exclusive Sample of Report 

https://www.visiongain.com/report/human-microbiome-market-2023/#download_sampe_div

How has COVID-19 had a Significant Negative Impact on the Human Microbiome Market? 

The COVID-19 reported to have dual negative impact on human microbiome market. The human microbiome clinical trials were disrupted due to COVID-19 pandemic. The direct interactions between the gut microbiome and COVID-19 were reported to have changes in faecal microbiome therapy (FMT) this has impacted the clinical trials which were in pipeline. Moreover, the COVID-19 impact was also seen in the lifestyle of patient population participating in the clinical trials leading to increased hygiene, change in food habits, intake of probiotics and medications to improve the immunity this consequently led to change in the human microbiota. The pandemic has put forth new challenges for research community including retention of patients in clinical trials, study design. Many companies had to put their clinical trials on -hold during the pandemic which had a negative economic impact on their balance sheets. During the pandemic, recruitment, sample sizing, collection of microbiome sample, storage and stools analysis for on-going clinical trials faced major roadblocks. Although, the psychological and psychiatric impact during the pandemic is known to change the gut environment, these have not been yet taken elucidated although their impact is considered to be significant. Therefore,COVID-19 has negatively impacted not only the operations of clinical trials but has also impacted the results of clinical trials in long term and also poses a major challenge for human microbiome players to mitigate its impact on their R&D studies.  

How will this Report Benefit you? 

Visiongain’s 276-page report provides 121 tables and 161 charts/graphs. Our new study is suitable for anyone requiring commercial, in-depth analyses for the human microbiome market, along with detailed segment analysis in the market. Our new study will help you evaluate the overall global and regional market for human microbiome. Get financial analysis of the overall market and different segments including by type, technology, therapeutics, product and company size and capture higher market share. We believe that there are strong opportunities in this fast-growing human microbiome market. See how to use the existing and upcoming opportunities in this market to gain revenue benefits in the near future. Moreover, the report will help you to improve your strategic decision-making, allowing you to frame growth strategies, reinforce the analysis of other market players, and maximise the productivity of the company. 

What are the Current Market Drivers? 

Microbiome Biomarker Discovery Supporting the Growth of Companion Diagnostics  

Microbiome biomarkers are expected to open new avenues of clinical diagnosis and treatment methodology as compared to the traditional biomarkers. There has been a significant research being conducted to identify these biomarkers and few of these studies have shown a strong correlation or dysbiosis or imbalance in the gut microbial community. For instance, Parkinson’s’ disease depict an increase in Lactobacillus, Akkermansia, Bifidobacterium and Verrucomicrobiacea while, roseburia, Faecalibaterium, prevolta and Blautia appear to be less. Similarly such dysbiosis have been identified in diseases such as IBD (which includes ulcerative colitis and Crohn’s Disease) and colorectal cancer. Some microbiome players are using their proprietary microbiome mining platforms for identification of these biomarkers. Many have collaborated with big pharma players to support microbiome as adjuvant therapies. For instance, in June 2022, the two companies BiomX and Boehringer Ingelheim collaborated to discover IBD microbiome biomarkers. BiomX will be utilizing its XMarker microbiome based biomarker discovery platform with the objective to find IBD biomarkers which are parallel to the Boehringer Ingelheim first in class pipeline drugs for treatment of IBD. Some of the other major players in this market include GLC Biotechnology Inc., GoodGut S.L., ZMD Group, Pescient Metabiomics, and LLC. Some companies are also focusing on vaginal microbiota for understanding and its correlation with in-vitro fertilization and microbiome analysis of cancer tissue.  This is being developed Micronoma (CA, U.S. based firm). However validation of these biomarkers is very important as many of them change in response to the external factors making it difficult to make the exact co-relation 

High Throughput Sequencing, Machine Learning (AI & Deep Learning) to Reinforce the Market Growth  

Technological advances using the next generation sequencing platforms have enabled the researchers to profile a plethora of microbial diversity. Low costs of sequencing is now permitting large scale studies of the microbial community. As most of the microbe exhibit identical 16SrRNA gene, the 16SrRNA is the most popular method used for functional classification of microbe genes. As not all the genes are represented in 16SrRNA, shotgun metagenomics sequencing method is gaining more preference. The short-gun metagenomics sequencing provides a direct measurement of all the genes present, which can be used as potential functional gene product for treatment. The large datasets are crucial for better understanding the microbial ecology for which Artificial intelligence and Machine Learning has proven to be instrumental for correlating the human health and microbial community gene profiles. Although machine learning techniques are considered extremely useful, they have their own set of challenges such as model appropriate for the characteristics of data, incomplete data-sets and lack of interpretability. Also, Artificial Intelligence aids to develop predictive models for personalized therapeutic interventions. Such interventions could include change in diet or use of prebiotics or post biotics or combination of both. Artificial intelligence is expected to support the growth of as a better diagnostic tool for gut microbiome research. Xbiome, China-based firm is using AI and microbiology in combination to decode the human gut for a novel drug discovery. Its proprietary AI – platform named X-Optim helps in accelerating the drug discovery through use of machine learning algorithms. The platform helps in early evaluation of drug candidate thereby fastening the drug approval processes. 

Download Exclusive Sample of Report 

https://www.visiongain.com/report/human-microbiome-market-2023/#download_sampe_div

Where are the Market Opportunities? 

Manufacturing of LBPs has been extremely challenging and is capital intensive. Very few innovator companies can carry the manufacturing operations in-house for example Enterome Bioscience, Finch Therapeutics, and Nubiyota. However, many start-ups lack expertise, availability of skilled labour, and expensive manufacturing processes including use of the bioreactors, upstream, and downstream processes. This has compelled the innovator firms to scout for contract service providers to commercialize their products at large scale through the use of highly specialized GMP-qualified manufacturing facilities. This has created new avenues for contract manufacturing firms that are specialized to deal with LBP products. For instance, in 2021, Seres Therapeutics inked an agreement with Bacthera to produce its lead SER-109 drug for CDI on commercialization. In addition, Bacthera has also established a dedicated Microbiome Center of Excellence on its Lonza campus in Switzerland. Another leading CDMO in this segment is Arranta Bio which plans to tap this market opportunity and announced 13,000 sq. Feet manufacturing facility in Massachusetts to complement its existing facilities in Watertown, Massachusetts and Gainesville, Florida, bringing the total manufacturing capacity at Arranta to over 230,000 square feet 

Competitive Landscape 

The major players operating in the human microbiome market are Rebiotix Inc., ( a Ferring Pharmaceutical company), Seres Therapeutics, Finch Therapeutics, Vedanta Biosciences, MaaT Pharma, Axial Therapeutics, Enterobiome, Enterome, Synlogic, BiomX, and Theriva Biologics (ex-Synthetic Biologics). These major players operating in this market have adopted various strategies comprising M&A, investment in R&D, collaborations, partnerships, regional business expansion, and new drugs for various therapeutic indications. 

Recent Developments 

  • On 22nd December 2022, Biomica Ltd, a subsidiary of Evogene Ltd (Israel) inked an agreement with the Shanghai Healthcare Capital to raise US$20 million through financing round. This capital raised by Biomica would help the company to accelerate its current ongoing clinical studies for drug candidates named BMC128 (Phase 1) and BMC333 (Phase 1) for therapeutic indications of immuno-oncology and Irritable Bowel Disease (IBD) respectively.  
  • On 22nd November 2022, AsiaBiome, a Hong Kong based start-up was acquired by Holobiome (U.S.). This acquisition will support Holobiome to access the robust donor network of Asian community and also explore the lucrative market of Asia in future. 

To access the data contained in this document please email [email protected]

To find more Visiongain research reports on the Pharma sector, click on the following links: 

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: [email protected]

About Visiongain 

Visiongain is one of the fastest-growing and most innovative independent market intelligence providers around, the company publishes hundreds of market research reports which it adds to its extensive portfolio each year. These reports offer in-depth analysis across 18 industries worldwide. The reports, which cover 10-year forecasts, are hundreds of pages long, with in-depth market analysis and valuable competitive intelligence data. Visiongain works across a range of vertical markets with a lot of synergies. These markets include automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors. Our customised and syndicated market research reports offer a bespoke piece of market intelligence customised to your very own business needs. 

Contact: 

Oliver Davison
Visiongain Reports Limited 
Telephone: +44 (0) 20 7336 6100 
Email: [email protected]
Web: www.visiongain.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

XtalPi Unveils XtalGazer: A Comprehensive AI-Driven Polymorph Selection Platform

Published

on

xtalpi-unveils-xtalgazer:-a-comprehensive-ai-driven-polymorph-selection-platform

CAMBRIDGE, Mass., March 28, 2024 /PRNewswire/ — XtalPi Inc., a leading global technology company in integrating artificial intelligence (AI) and robotics to advance the discovery of groundbreaking medicine and innovative materials, announced today the launch of its proprietary comprehensive solid form discovery and selection platform, XtalGazer. This advanced platform aims to significantly improve the polymorph selection process for the pharmaceutical industry by integrating AI- and automation-powered experimental and computational approaches.

XtalGazer provides a total solution for delivering high-quality polymorph screening and selection methods to expedite drug development and mitigate risks. It represents a paradigm shift in solid-state research, moving from the traditional trial-and-error approach to a data-driven, design-led methodology. The platform provides an expansive suite of foundational tools to accelerate polymorph discovery, characterization, and selection process, empowering pharmaceutical companies to conduct thorough research with less active pharmaceutical ingredient (API) in shorter development cycles.
A key component of XtalGazer is XtalCSP, a crystal structure prediction platform to perform global searches of crystal structures for target molecules and the other optional components in the corresponding searching space, offering a deep insight into possible stable forms. Furthermore, crystallization strategy recommendations will provide AI-backed experimental design to help avoid human bias. XtalGazer also utilizes MicroED to rapidly elucidate crystal structures from powder samples, reducing the need for growing single crystals.
XtalPi’s launch of XtalGazer marks another significant step in the company’s ongoing exploration of solid-state research. From crystal structure prediction platforms being one of the first products to launch at XtalPi, to today’s comprehensive polymorph selection platform, XtalPi will keep fulfilling its promise to solving challenging problems in this space. XtalPi will continue to deliver faster, more accurate, and more comprehensive approaches to building an ecosystem for the R&D process in solid-state, pre-formulation and crystallization.
For more information about XtalPi, please visit www.xtalpi.com.
About XtalPi:
XtalPi is an innovative technology company powered by artificial intelligence (AI) and robotics. Founded in 2015 on the MIT campus, XtalPi is dedicated to driving intelligent and digital transformation in the life science and new materials industries. With tightly interwoven quantum physics, AI, cloud computing, and large-scale clusters of robotic workstations, XtalPi offers a range of technology solutions, services, and products to accelerate and empower innovation for biopharmaceutical and new materials companies worldwide.
Media Contact: Vivienne [email protected]
Logo – https://mma.prnewswire.com/media/632519/XtalPi_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/xtalpi-unveils-xtalgazer-a-comprehensive-ai-driven-polymorph-selection-platform-302102794.html

Continue Reading

Artificial Intelligence

ICIS and Base Oil News Announce Partnership to Enhance Market Insights

Published

on

icis-and-base-oil-news-announce-partnership-to-enhance-market-insights

LONDON, March 28, 2024 /PRNewswire/ — ICIS, a global source of commodity intelligence, is pleased to announce a strategic partnership with Base Oil News, a premier news outlet founded by industry expert Iain Pocock that provides in-depth coverage of the base oils and lubricants market. This collaboration marks a significant milestone in the dissemination and exchange of critical market data and insights.

With more than two decades of journalism experience at Bloomberg, Reuters, and Argus Media, Iain Pocock brings unparalleled expertise to this partnership. His deep understanding of illiquid energy markets makes him a credible and influential figure in the industry. Since November 2023, Iain has been working closely with ICIS to share and exchange valuable data and insights, enhancing the services both platforms offer to the base oils and lubricants market.
Through the collaboration, Iain integrates ICIS’ extensive content and data resources in Base Oil News market coverage. In return, he contributes market insights to ICIS News, including expert and exclusive analysis of supply and demand dynamics, price margins, and other critical market drivers. This exchange ensures that subscribers of both ICIS and Base Oil News have access to the most comprehensive, timely, and accurate market information, empowering them to make informed decisions.
“It’s a very exciting partnership – where we leverage each other’s strengths and provide actionable insights to our customers,” said Iain Pocock, Founder of Base Oil News. “The market is the winner.”
“As ICIS is already the world’s most trusted pricing benchmark for base oils, this collaboration with Iain Pocock and Base Oil News provides an even stronger and deeper service to our customers,” said Stephen Burns, Editorial Director at ICIS. “Iain’s expertise and extensive industry connections are invaluable, and we have established a fruitful partnership that benefits the market at large.”
For the latest insights from Iain Pocock on ICIS News, visit ICIS News.  
About ICIS
ICIS – Independent Commodity Intelligence Services – helps businesses through seamlessly delivering data and analytics, across the chemical, fertilizer and energy markets. A trusted source and benchmark for price information and insight across key commodities markets worldwide. Our independent, transparent market intelligence informs thousands of quality decisions every day, taking the pressure out of negotiations and giving customers space for more innovative thinking, through published datasets including price assessments, price forecasts, supply and demand fundamentals and more.
Over 150 years of shaping the world by connecting markets to optimise the world’s valuable resources. With a global team of more than 600 experts, ICIS has employees based in London, New York, Houston, Karlsruhe, Milan, Mumbai, Singapore, Guangzhou, Beijing, Shanghai, Dubai, Sao Paulo, Seoul, Tokyo and Perth.
ICIS is part of RELX, a FTSE15 company with a market cap of £64bn and an employee base of over 30,000 experts across 40 countries.
About RELX
RELX is a global provider of information and analytics for professional and business customers across industries. The Group serves customers in more than 180 countries and has offices in about 40 countries. It employs approximately 30,000 people of whom almost half are in North America. RELX PLC is a London listed holding company which owns 52.9% of RELX Group. RELX NV is an Amsterdam listed holding company which owns 47.1% of RELX Group. The shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX and RENX. Total market capitalisation is approximately £64bn | €75bn | $81bn.
Logo: https://mma.prnewswire.com/media/619935/4277787/ICIS_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/icis-and-base-oil-news-announce-partnership-to-enhance-market-insights-302102782.html

Continue Reading

Artificial Intelligence

Trianz Welcomes Israel Abraham as Vice President of Services for Extrica.ai – The Data to AI Platform

Published

on

trianz-welcomes-israel-abraham-as-vice-president-of-services-for-extrica.ai-–-the-data-to-ai-platform

SANTA CLARA, Calif., March 28, 2024 /PRNewswire/ — Digital transformation technology & services company Trianz is pleased to announce the appointment of Israel Abraham as Vice President of Extrica Platform Services.

Trianz has embarked on a transformative journey, redefining its value proposition with an ‘IP Led’ model, with a commitment to deliver the fastest time to value, lowest human dependence, and highest ROI. Central to this approach are our hyper-automated platforms, Concierto.Cloud, Extrica.AI, and Pulse, driving industry-leading transformations in cloud, data and analytics, AI, and the digital workplace.
Israel Abraham is a very well-known pioneer and industry leader in AI, data management, and analytics systems, with over three decades of experience. He joins as the services leader for Extrica- the Trianz Data to AI platform, which productizes data, provides data a face and purpose, and accelerates time to insights and AI by 50% or more. In the role of Extrica Services leader, Israel will lead the shaping, visioning, and delivery of Extrica.ai based enterprise wide datamesh, BI, and AI solutions for customers worldwide.
“We are thrilled to welcome Israel Abraham to the Trianz family,” said Sri Manchala, CEO of Trianz and author of Crossing the Digital Faultline. “He is a leader in modernization as well as conceptualization of data platforms anew. Israel’s prior background in the industry with financial services and insurance giants underscores our commitment to securing top-tier talent that brings real-world experiences and needs to our technology platforms. As we continue to broaden our footprint in the digital transformation space, Israel’s visionary leadership and practical experience will serve as the cornerstone in accelerating insights and AI to deliver transformative value to our clients.”
Having played pivotal roles in highly reputed and large organizations such as Liberty Mutual Insurance, MassMutual, Safeco, and CNA Insurance, Israel has garnered recognition as a seasoned leader in big data and AI cloud implementations. His accolades include the prestigious 2014 Ventana Research IT Innovation Award, the 2009 Informatica MDM Innovation Award, and three filed Data Engineering patents in the last four years.
“Trianz has been at the forefront of digital innovation, and Extrica.ai is a paradigm shifting data to AI platform that completely changes how analytics and AI are delivered- much faster, taking business ahead of change. I am excited to scale the adoption of the Extrica platform, which has attracted attention from giants across the industry and hyperscalers,” said Israel Abraham. “I look forward to engaging with customers, bringing my own experiences, and collaborating with the talented team at Trianz to further enhance the capabilities of the Extrica Platform Services to transform data & AI strategies, execution, and outcomes for customers.”
About Trianz
Trianz is a leading-edge technology platforms and services company that accelerates digital transformations at Fortune 100 and emerging companies worldwide in data & analytics, digital experiences, cloud infrastructure, and security. Our ‘IP Led Transformations’ approach, informed by insights from a recent global study spanning 20+ industries and 5000+ companies, addresses challenges posed by the rapid pace of AI-driven transformation, digital talent scarcity, and economic uncertainty. Our IP and platforms, including Concierto, Extrica, and Pulse, revolutionize cloud adoption, data analytics, and AI insights, empowering organizations to navigate the complexities of digital transformation seamlessly.
Founded in California and with an organization of over 2,000 associates across the United States and India, Trianz is a Premier Partner of AWS, consistently rated #1 by clients for value delivery over the past five years. Trianz has been ranked as one of the best Consulting Firms by Forbes and has been certified as a Great Place to Work for three years in a row. To learn more about Trianz, email [email protected] or visit www.trianz.com.
Watch Trianz CEO Sri Manchala’s insightful interview with Bloomberg on Partner | Crossing The Digital Faultline & Leading Towards Transformative Success – YouTube and delve deeper into his book Crossing the Digital Faultline at Crossing the Digital Faultline | Trianz.
Trianz Media [email protected] +1-408-387-5800
Logo: https://mma.prnewswire.com/media/626944/1199800/Trianz_Logo.jpg
 

View original content:https://www.prnewswire.co.uk/news-releases/trianz-welcomes-israel-abraham-as-vice-president-of-services-for-extricaai–the-data-to-ai-platform-302102589.html

Continue Reading
Advertisement

Latest News

Trending